A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2018
At a glance
- Drugs TLC 388 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 08 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 08 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.